Business Context and Reporting Period
This Form 6-K filing by Redhill Biopharma Ltd. covers the month of May 2025. The report addresses a corporate governance event: the adjournment of the Annual General Meeting of Shareholders originally scheduled for May 5, 2025, due to a lack of required legal quorum.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural notice regarding a shareholder meeting and contains no financial performance data.
Material Changes
The primary material change is the postponement of the Annual General Meeting. The Board of Directors has rescheduled the meeting to May 26, 2025, at 3:00 p.m. Israel time, to be held at the Company's offices in Tel-Aviv, Israel.
Guidance, Outlook, and Risks
There is no financial guidance, outlook, or management commentary on business operations in this filing. The document outlines specific logistical updates for shareholders:
- Voting will be re-opened at 9:00 a.m. EST on May 6, 2025.
- All votes submitted to The Bank of New York Mellon must be received by 12:00 p.m. EST on May 21, 2025.
Key Facts for Investor Verification
- Verify the new meeting date of May 26, 2025, and the location in Tel-Aviv.
- Confirm the updated voting deadline of 12:00 p.m. EST on May 21, 2025, for American Depositary Shares.
- Note that the original meeting on May 5, 2025, was adjourned due to insufficient quorum.